2/2
08:05 am
mnpr
Monopar Therapeutics (NASDAQ:MNPR) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $104.00 price target on the stock.
Medium
Report
Monopar Therapeutics (NASDAQ:MNPR) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $104.00 price target on the stock.
2/2
07:55 am
mnpr
Rating for MNPR
Medium
Report
Rating for MNPR
1/29
08:27 am
mnpr
Monopar Therapeutics (NASDAQ:MNPR) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $100.00 price target on the stock.
Medium
Report
Monopar Therapeutics (NASDAQ:MNPR) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $100.00 price target on the stock.
1/29
08:07 am
mnpr
Rating for MNPR
Low
Report
Rating for MNPR
1/21
10:12 am
mnpr
Monopar Therapeutics (NASDAQ:MNPR) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
Low
Report
Monopar Therapeutics (NASDAQ:MNPR) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
1/14
08:04 am
mnpr
Monopar Therapeutics (NASDAQ:MNPR) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $104.00 price target on the stock.
Medium
Report
Monopar Therapeutics (NASDAQ:MNPR) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $104.00 price target on the stock.
1/14
05:00 am
mnpr
Rating for MNPR
Medium
Report
Rating for MNPR
1/9
08:00 am
mnpr
Rating for MNPR
Low
Report
Rating for MNPR
1/9
08:00 am
mnpr
Rating for MNPR
Low
Report
Rating for MNPR
1/9
07:00 am
mnpr
Monopar Therapeutics (NASDAQ:MNPR) is now covered by analysts at Morgan Stanley. They set an "overweight" rating on the stock.
Low
Report
Monopar Therapeutics (NASDAQ:MNPR) is now covered by analysts at Morgan Stanley. They set an "overweight" rating on the stock.
1/9
07:00 am
mnpr
Monopar Therapeutics (NASDAQ:MNPR) is now covered by analysts at Morgan Stanley. They set an "overweight" rating on the stock.
Low
Report
Monopar Therapeutics (NASDAQ:MNPR) is now covered by analysts at Morgan Stanley. They set an "overweight" rating on the stock.
1/9
05:11 am
mnpr
Monopar Therapeutics initiated with an Overweight at Morgan Stanley
Low
Report
Monopar Therapeutics initiated with an Overweight at Morgan Stanley
1/9
05:11 am
mnpr
Monopar Therapeutics initiated with an Overweight at Morgan Stanley
Low
Report
Monopar Therapeutics initiated with an Overweight at Morgan Stanley
11/14
07:22 am
mnpr
Monopar Therapeutics (NASDAQ:MNPR) was downgraded by analysts at Raymond James Financial, Inc. from a "strong-buy" rating to an "outperform" rating.
High
Report
Monopar Therapeutics (NASDAQ:MNPR) was downgraded by analysts at Raymond James Financial, Inc. from a "strong-buy" rating to an "outperform" rating.
11/14
06:52 am
mnpr
Rating for MNPR
High
Report
Rating for MNPR
11/14
06:52 am
mnpr
Rating for MNPR
High
Report
Rating for MNPR
11/14
06:05 am
mnpr
Monopar downgraded to Outperform from Strong Buy at Raymond James
High
Report
Monopar downgraded to Outperform from Strong Buy at Raymond James
11/14
06:05 am
mnpr
Monopar downgraded to Outperform from Strong Buy at Raymond James
High
Report
Monopar downgraded to Outperform from Strong Buy at Raymond James
11/13
04:14 pm
mnpr
Rating for MNPR
High
Report
Rating for MNPR